Product How it works Pricing Blog FAQ About Contact
Arcutis Biotherapeutics

Arcutis Biotherapeutics (NASDAQ: ARQT) revenue

Arcutis Biotherapeutics reported revenue of $376.1m for fiscal 2025, 91.3% more than in fiscal 2024 ($196.5m).

Arcutis Biotherapeutics has grown its revenue for 3 years in a row, and fiscal 2025 is the highest of its 6 fiscal years on record.

Revenue, in millions of US dollars0.020200.020213.7202259.62023196.52024376.12025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Revenue by fiscal year

Fiscal yearRevenueChangeOperating profitOperating margin
2025$376.1m+91.3%−$12.2m−3.3%
2024$196.5m+229.7%−$128.4m−65.3%
2023$59.6m+1,517.1%−$241.1m−404.5%
2022$3.7m—−$301.6m−8,183.0%
2021$0.0m—−$206.5m—
2020$0.0m—−$136.6m—

The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.

Arcutis Biotherapeutics revenue compared with its sector

By revenue for its latest fiscal year, Arcutis Biotherapeutics ranks 210th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Arcutis Biotherapeutics, 91.3%.

RankCompanyRevenueRevenue growth
208thCareDx$379.8m13.8%
209thTwist Bioscience$376.6m20.3%
210thArcutis Biotherapeutics$376.1m91.3%
211thMannKind$349.0m22.2%
212thInogen$348.7m3.9%

Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.

Questions about the revenue of Arcutis Biotherapeutics

How much revenue did Arcutis Biotherapeutics make in fiscal 2025?
Arcutis Biotherapeutics reported revenue of $376.1m for fiscal 2025, compared with $196.5m in fiscal 2024.
What was the best year for revenue at Arcutis Biotherapeutics?
Of its last 6 fiscal years, fiscal 2025, with $376.1m.
Where does Arcutis Biotherapeutics rank in its sector by revenue?
It ranks 210th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
Where do the figures for Arcutis Biotherapeutics come from?
From the annual report (Form 10-K) that Arcutis Biotherapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that Arcutis Biotherapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Arcutis Biotherapeutics: the Arcutis Biotherapeutics page · annual accounts · net income · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.